Integrating semaglutide into obesity management - a primary care perspective

Postgrad Med. 2022 Jan;134(sup1):37-49. doi: 10.1080/00325481.2022.2149964.

Abstract

This final article in the supplement aims to summarize a clinical approach for weight management geared toward primary care practitioners, offering practical advice about how to integrate weight management into day-to-day practice. To achieve long-term successful weight loss, a comprehensive multimodal approach is recommended, focusing on both lifestyle modification and appropriate use of therapy. Once-weekly subcutaneous semaglutide 2.4 mg is a novel treatment that can be used as an adjunct to lifestyle modification for the management of overweight and obesity. Key considerations are presented to support its optimal administration in conjunction with lifestyle modification, with a focus on assessing suitability and the importance of dose escalation and monitoring.

Keywords: Obesity; clinical practice; glucagon-like peptide-1 receptor agonist; guidelines; primary care; semaglutide.

Publication types

  • Review

MeSH terms

  • Diabetes Mellitus, Type 2* / drug therapy
  • Glucagon-Like Peptides / therapeutic use
  • Humans
  • Hypoglycemic Agents / therapeutic use
  • Obesity Management*
  • Primary Health Care

Substances

  • semaglutide
  • Hypoglycemic Agents
  • Glucagon-Like Peptides